Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the cost per quality adjusted life year (QALY) over 10 years. For predominantly classic AMD, the efficacy of bevacizumab relative to ranibizumab would have to be around 40% for the latter to achieve 30k pound per QALY, a NICE threshold. Similar but worse results applied to the other main forms of AMD, minimally occult and occult with no classic lesions. The price of ranibizumab would have to be drastically reduced for it to be cost effective. Continued unlicensed use of bevacizumab raises ethical, legal and policy questions. Public pressure may be the most potent weapon in persuading Genentech to license bevacizumab for AMD.
ranibizumab, photodynamic therapy, choroidal neovascularization secondary, eye, lesions, efficacy, macular degeneration, treatment, cost-effectiveness, intravitreal bevacizumab, drugs, amd, model, verteporfin
1244-1246
Raftery, J.
27c2661d-6c4f-448a-bf36-9a89ec72bd6b
Clegg, A.
838091f5-39df-4dbe-a369-675b26f2301b
Jones, J.
3408ebe3-fdb8-4ff9-a3a3-031281f02092
Tan, S.C.
5c5b75da-c65a-4dfb-840a-a66642479233
Lotery, A.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
2007
Raftery, J.
27c2661d-6c4f-448a-bf36-9a89ec72bd6b
Clegg, A.
838091f5-39df-4dbe-a369-675b26f2301b
Jones, J.
3408ebe3-fdb8-4ff9-a3a3-031281f02092
Tan, S.C.
5c5b75da-c65a-4dfb-840a-a66642479233
Lotery, A.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Raftery, J., Clegg, A., Jones, J., Tan, S.C. and Lotery, A.
(2007)
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.
British Journal of Ophthalmology, 91 (9), .
(doi:10.1136/bjo.2007.116616).
Abstract
Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the cost per quality adjusted life year (QALY) over 10 years. For predominantly classic AMD, the efficacy of bevacizumab relative to ranibizumab would have to be around 40% for the latter to achieve 30k pound per QALY, a NICE threshold. Similar but worse results applied to the other main forms of AMD, minimally occult and occult with no classic lesions. The price of ranibizumab would have to be drastically reduced for it to be cost effective. Continued unlicensed use of bevacizumab raises ethical, legal and policy questions. Public pressure may be the most potent weapon in persuading Genentech to license bevacizumab for AMD.
This record has no associated files available for download.
More information
Published date: 2007
Keywords:
ranibizumab, photodynamic therapy, choroidal neovascularization secondary, eye, lesions, efficacy, macular degeneration, treatment, cost-effectiveness, intravitreal bevacizumab, drugs, amd, model, verteporfin
Identifiers
Local EPrints ID: 62552
URI: http://eprints.soton.ac.uk/id/eprint/62552
ISSN: 0007-1161
PURE UUID: bad912fd-2bef-4715-939e-3347344e104f
Catalogue record
Date deposited: 11 Sep 2008
Last modified: 16 Mar 2024 03:31
Export record
Altmetrics
Contributors
Author:
J. Jones
Author:
S.C. Tan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
